On May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment patterns, and the United States’ leadership in biomedical innovation.
Countdown to SLAS Europe: NestEgg Labs BV
Associations, Latest NewsJust few days to go until SLAS Europe 2025 takes place in Hamburg from 20–22 May. Organized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features Netherlands-based NestEgg Labs BV.
Countdown to SLAS Europe: Unicorn Biotechnologies Ltd
Associations, Latest NewsJust one week to go until SLAS Europe 2025 takes place in Hamburg from 20–22 May. Organized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features UK-based Unicorn Biotechnologies.
America’s Drug Price Revolution: A Boon for Patients or a Blow to Innovation?
Latest News, OpinionOn May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment patterns, and the United States’ leadership in biomedical innovation.
Azafaros BV bags €132m Series B financing
Latest NewsBelgian lysosomal storage disease specialist Azafaros BV has added a new lead investor to its portfolio. In addition to €25m Series A leader Forbion, Jeito Captial co-led a €132m Series B round aimed at advancing two pivotal trials of Azafaros‘ lead compound nizabagloustat (AZ-3102).
From Emissions to Solutions: “Best CO2 Utilisation 2025” Innovation Award
BackgroundUP Catalyst, Far Eastern New Century Corporation, and Oxylus Energy were recognised at the “Best CO2 Utilisation 2025” Innovation Award for transforming carbon emissions into high-performance battery materials, sustainable plastics for footwear and textiles, and methanol fuel, marking major strides toward a renewable carbon future.
Countdown to SLAS Europe: ORYL Photonics SA
Associations, Latest NewsWith only one week remaining until Europe’s largest event focused on laboratory automation and drug screening, preparations for SLAS Europe 2025 are well under way. Organised by the Society for Laboratory Automation and Screening (SLAS), the conference will be held in Hamburg from 20–22 May. As part of a dedicated series, European Biotechnology Magazine is highlighting twelve of the most innovative SMEs currently operating in the sector. Among them is Switzerland’s ORYL Photonics SA.
eXmoor Pharma and KU Leuven join forces in AAV production
Latest NewsBritish cell and gene therapy CDMO eXmoor Pharma plc, and KU Leuven which has just launched a translational cell and gene therapy hub in Belgium have inked a strategic collaboration supporting the hub’s work in four areas.
ENVLPE improves gene and cell therapy
Latest NewsScientists at German Helmholtz Centre Munich have presented a new transport system for gene and cell therapy that overcomes the limitations of viral vectors. An in vivo gene therapy for hereditary blindness corrected the defect in the Rpe65 gene ten times more efficiently than was possible with viral vectors.
SLAS names SLAS Europe Award finalists
Associations, Latest NewsThe Society of Laboratory Automation and Screening (SLAS) has named the five finalists for the SLAS Europe Poster Award, New Product Award and the SLAS Ignite Award that will be honored in Hamburg on 21 and 22 May, 2025.
Countdown to SLAS Europe: Phabioc GmbH
Associations, Latest NewsOnly three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: Phabioc GmbH.